FDA clears Impax Labs' EMVERM tablets

• The FDA approves Impax Laboratories' (IPXL) supplemental New Drug Application (sNDA) for EMVERM (mebendazole) 100 mg chewable tablets for the treatment of pinworm, roundworm and hookworm, in single or mixed infections. Pinworm, three times more common than head lice, is a highly contagious parasite that infects 40M Americans each year.
• Commercial distribution will commence next quarter.